Validation of COVID19 diagnostic testing by LCMSMS [COVID-19]

  • Research type

    Research Study

  • Full title

    Validation of COVID19 diagnostic testing by liquid chromatography mass spectrometry

  • IRAS ID

    296024

  • Contact name

    Holly Gettings

  • Contact email

    holly.gettings@gstt.nhs.uk

  • Sponsor organisation

    Guy's and St Thomas' NHS Foundation Trust

  • Duration of Study in the UK

    0 years, 2 months, 10 days

  • Research summary

    COVID testing by LC-MS/MS is part of the DHSC ‘Operation Moonshot’ programme which is a collaboration between industry, academia and the NHS. A novel method to detect COVID-19 has been developed using liquid chromatography mass spectrometry (LC-MS/MS). The initial validation indicates that this method compares well to existing PCR based methods. The next stage is validation of the method in a clinical laboratory and UKAS accreditation. The LCMSMS test offers a number of advantages; it relies upon a different supply chain to the existing COVID tests; it will be provided by a different group of scientists (biochemists) thus relieving pressure on Virology staff; it has high throughout with a single instrument being able to analyse approx. 1000 samples each day.
    To translate the LC-MS/MS test from the academic laboratory and into a NHS clinical laboratory, we urgently need access to additional samples to validate the new method and gain UKAS accreditation.
    This application is a request to collect an additional combined nose and throat swab and a saliva sample from patients presenting to the Emergency Department who are already having a routine nose and throat swab collected for SARSCoV-2 PCR testing. The research swab and saliva samples will be collected into an ethanol buffer which deactivates the virus at the point of collection, thus simplifying the logistics of sample handling and processing. The samples will be pseudoanonymised and there will be no impact on the clinical care of the patient, nor will the research results be returned to the participant. There will be no impact on standard of care for the participants as a result of this study.

  • REC name

    Wales REC 3

  • REC reference

    21/WA/0101

  • Date of REC Opinion

    18 Mar 2021

  • REC opinion

    Favourable Opinion